SCHEMBL1103398

SCHEMBL1103398

c1ccc(-c2ccc(-c3ccccc3-c3c4ccccc4c(-c4ccccc4)c4c3cnc3ccccc34)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
MAPT P10636 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
HTT P42858 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
HPGD P15428 3/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ADORA2A P29274 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103391 0.97 ALDH1A1 (0.38) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103361 0.95 CDK4 (0.37) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103266 0.92 CDK4 (0.39) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103249 0.89 ESR1 (0.41) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103301 0.89 ESR1 (0.41) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103380 0.89 ESR1 (0.41) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103464 0.89 ESR1 (0.41) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103509 0.88 MET (0.42) ALDH1A1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL1103394 0.88 ALDH1A1 (0.39) ALDH1A1MAPTNPSR1HTTSMN1; SMN2
SCHEMBL1103426 0.88 ALDH1A1 (0.39) ALDH1A1MAPTNPSR1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885MAPT 3162/4885NPSR1 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.